Ascendis Pharma is a Denmark-based biopharmaceutical company that develops long-acting prodrug therapies, primarily in endocrinology and rare diseases. (This entry references an Ascendis Pharma convertible bond.)
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Louis Bacon / Moore | 55 | Added +39% | 125,000 | $26,655,000 | 0.4% |
| Howard Marks / Oaktree | 69 | Trimmed -30% | 700,000 | $994,315 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.